Table 1.
Characteristics of enrolled patients with advanced gastric cancer (n = 117)
| Characteristics | No. of patients (%) | Median (range) |
|---|---|---|
| Age (years) | 63 (34–89) | |
| Gender | ||
| Male | 41 (35.0%) | |
| Female | 76 (65.0%) | |
| Tumor location | ||
| Upper | 9 (7.7%) | |
| Middle | 46 (39.3%) | |
| Lower | 60 (51.3%) | |
| Multiple | 2 (1.7%) | |
| Histopathology | ||
| PAC/TAC | 72 (61.6%) | |
| PDAC | 30 (25.6%) | |
| SRC/mucinous carcinoma | 15 (12.8%) | |
| Lauren classification | ||
| Intestinal | 41 (35.0%) | |
| Non-intestinal | 76 (65.0%) | |
| pT stage | ||
| T2 stage | 40 (34.2%) | |
| T3 stage | 46 (39.3%) | |
| T4 stage | 31 (26.5%) | |
| Lymph node metastasis | ||
| Absence | 37 (31.6%) | |
| Presence | 80 (68.4%) | |
| TNM stage | ||
| Stage I | 23 (19.7%) | |
| Stage II | 44 (37.6%) | |
| Stage III | 50 (42.7%) | |
| Tumor size (cm) | 4.9 (1.5–17.0) | |
| Adjuvant treatment | ||
| Yes | 78 (66.7%) | |
| No | 39 (33.3%) | |
| Serum CRP (mg/dL) | 2.02 (0.01–78.02) | |
| NLR | 2.20 (0.71–8.60) | |
| PLR | 141.97 (2.93–425.43) | |
| SUVmaxT | 4.85 (2.19–24.60) | |
| VAT attenuation | − 92.38 (− 108.42 to − 73.17) | |
| VAT SUV | 0.45 (0.22–0.90) |
PAC papillary adenocarcinoma, TAC tubular adenocarcinoma, PDAC poorly differentiated adenocarcinoma, SRC signet-ring cell carcinoma, CRP C-reactive protein, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SUVmaxT maximum standardized uptake value of primary tumor, VAT visceral adipose tissue, SUV standardized uptake value